News & Media
Stemline Therapeutics Inc., a wholly owned subsidiary of Menarini Group, Receives Approval from U.S. FDA for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published on January 30, 2023
Radius Health’s TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Published on December 20, 2022
European Commission Approves ELADYNOS (Abaloparatide) for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture
Published on December 19, 2022
Radius Appoints Ed Cinca as Chief Commercial Officer
Published on October 27, 2022
Radius’ Abaloparatide Receives Positive CHMP Opinion for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture
Published on October 14, 2022
Radius Announces Publication of Abaloparatide Phase 3 ATOM Trial Data in the Journal of Bone and Mineral Research
Published on October 13, 2022
Radius Appoints Scott Briggs as Chief Executive Officer
Published on October 12, 2022
Teijin Pharma Receives Additional Approval in Japan for Abaloparatide Acetate as Treatment for Osteoporosis
Published on September 5, 2022
Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
Published on August 19, 2022
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
Published on August 15, 2022